REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meeting
The first presentation will feature data from the RGX-314 Phase I/II subretinal trial for the treatment of wet age-related macular degeneration (wet AMD). Details are as follows:
Title: Update on the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD
Presenter:
Date/time: Available on-demand
Session title: RET07 – Gene- and Cell-Based Therapies
The second presentation will include data from preclinical studies of suprachoroidal delivery of RGX-314. Details are as follows:
Title: Viral and Nonviral Suprachoroidal Ocular Gene Transfer
Presenter: Peter A Campochiaro, M.D., Director,
Date/time:
Session title: RET07V – Gene- and Cell-Based Therapies
About REGENXBIO Inc.
Contacts:
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com
Media:
david.rosen@argotpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2020-annual-meeting-301169240.html
SOURCE